{
  "docId": "019de076-2351-76a2-9dc5-1c75bf1dd158",
  "docSlug": "905d9ceaf5cb608feb86b583a8401e54",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 45,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 60,
  "notes": "Includes footnotes regarding rounding, CER, and definitions of R&D, SG&A, and EPS.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2351-76a2-9dc5-1c75bf1dd158/10",
  "deckHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158",
  "deckJsonHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158.json",
  "deckAnchorHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1. Total operating expense includes distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbeaae8a-1f8d-4e74-87f8-fbf5d3a12dee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.82,
        "x": 0.14,
        "y": 0.22
      },
      "kind": "table",
      "text": "Financial performance table showing Revenue, Gross Margin, Operating Expenses, Operating Profit, and Core EPS for 9M and Q3 2023.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2e6882f-44d1-4caf-8bb9-aa053b34d202",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "9M 2023 – Core profit and loss",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "495c8e1e-fa60-4a5a-a2ed-486953686416",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4272c71f-edd6-48f7-a353-789a42575177",
      "evidence": "The document walks through a logical chain of financial performance, portfolio evolution, and R&D highlights",
      "position": 0,
      "objective": "How AstraZeneca's diversified portfolio drives growth",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}